Biology’s Arnold Caplan weighs in on whether FDA should review stem-cell treatments

Boom in unproven cell therapies intensifies regulatory debate

Nature: Biology Professor Arnold Caplan weighed in on the debate over whether the Federal Drug Administration should review stem-cell treatments conducted by clinics.